Table 1 Baseline characteristics
Tertiles of CV of FPG | T1 ≤ 0.157 | T2 0.157–0.249 | T3 > 0.249 | P value |
|---|---|---|---|---|
n | 146 | 146 | 145 | Â |
Demographic characteristics & clinical measures | ||||
 Male | 126 (86.3) | 124 (84.9) | 120 (82.8) | 0.702 |
 Age, years | 61.79 ± 11.24 | 63.15 ± 11.54 | 63.96 ± 11.67 | 0.268 |
 BMI, kg/m2 | 24.68 ± 3.12 | 25.18 ± 4.78 | 25.28 ± 3.48 | 0.387 |
 Systolic BP, mmHg | 122.26 ± 17.43 | 124.47 ± 19.92 | 120.75 ± 20.56 | 0.284 |
 Diastolic BP, mmHg | 82.78 ± 81.65 | 75.56 ± 12.19 | 72.83 ± 12.42 | 0.217 |
Medical history | ||||
 Hypertension | 76 (52.1) | 104 (71.2) | 92 (63.4) | 0.003 |
 Duration of diabetes, years | 6.38 ± 3.93 | 6.68 ± 3.90 | 10.77 ± 7.16 | < 0.001 |
 Current smoker | 68 (46.6) | 76 (52.1) | 65 (44.8) | 0.456 |
Laboratory values | ||||
 HbA1C,  % | 6.23 ± 0.94 | 6.69 ± 1.41 | 7.54 ± 1.70 | < 0.001 |
 FPG, mmol/L | 5.77 (5.12–6.70) | 7.67 (6.76–9.33) | 10.70 (7.91–13.34) | < 0.001 |
 PPG (2 h), mmol/L | 8.65 (6.88–11.27) | 11.18 (7.59–12.97) | 11.79 (9.71–15.56) | < 0.001 |
 Fasting insulin, µU/mL | 10.72 (8.35–15.52) | 9.42 (5.80–15.80) | 12.00 (8.33–24.78) | 0.003 |
 Postparandial insulin (2 h), µU/mL | 56.23 (33.60–109.03) | 37.31 (16.96–65.80) | 27.92 (13.27–75.63) | < 0.001 |
 Triglyceride, mmol/L | 1.63 (1.32–2.21) | 1.54 (1.02–2.05) | 1.58 (1.11–2.02) | 0.033 |
 Total cholesterol, mmol/L | 4.36 ± 0.95 | 4.53 ± 1.18 | 4.56 ± 1.35 | 0.273 |
 HDL cholesterol, mmol/L | 0.99 ± 0.28 | 1.02 ± 0.27 | 1.01 ± 0.24 | 0.734 |
 LDL cholesterol, mmol/L | 2.57 ± 0.86 | 2.81 ± 0.95 | 2.89 ± 1.15 | 0.020 |
 Non-HDL cholesterol, | 3.36 ± 0.96 | 3.51 ± 1.12 | 3.53 ± 1.32 | 0.388 |
eGFR, mL/min/1.73m2 | 93.90 ± 15.42 | 97.26 ± 22.73 | 97.93 ± 33.81 | 0.343 |
 hsCRP, mg/L | 3.01 (1.28–8.28) | 2.73 (0.84–19.00) | 4.88 (1.79–26.90) | 0.062 |
 Peak troponin I | 4.23 (0.40–15.85) | 8.37 (3.34–48.53) | 8.80 (4.63–69.11) | < 0.001 |
Diseased vessels | ||||
 1-vessel | 50 (34.2) | 50 (34.2) | 33 (22.8) |  |
 2-vessel | 52 (35.6) | 64 (43.8) | 61 (42.1) | 0.040 |
 3-vessel | 44 (30.1) | 32 (21.9) | 51 (35.2) |  |
 MVD | 96 (65.8) | 96 (65.8) | 112 (77.2) | 0.056 |
Culprit vessel | ||||
 LM | 0 (0.0) | 2 (1.3) | 4 (2.3) |  |
 LAD | 86 (55.1) | 98 (62.0) | 86 (50.0) |  |
 LCX | 28 (17.9) | 20 (12.7) | 39 (22.7) | 0.100 |
 RCA | 42 (26.9) | 38 (24.1) | 43 (25.0) |  |
Medication use, n(%) | ||||
 Aspirin | 138 (94.5) | 138 (94.5) | 133 (91.7) | 0.546 |
 P2Y12 inhibitor | 138 (94.5) | 134 (91.8) | 130 (89.7) | 0.311 |
 Beta blocker | 134 (91.8) | 122 (83.6) | 122 (84.1) | 0.064 |
 ACEI/ARB | 112 (76.7) | 110 (75.3) | 105 (72.4) | 0.694 |
 CCB | 6 (4.1) | 14 (9.6) | 25 (17.2) | 0.001 |
 Statin | 104 (71.2) | 120 (82.2) | 132 (91.0) | < 0.001 |
 Biguanides | 14 (9.6) | 20 (13.7) | 38 (26.2) | < 0.001 |
 Sulfonylureas | 6 (4.1) | 16 (11.0) | 24 (16.6) | 0.002 |
 Meglitinides | 4 (2.7) | 0 (0.0) | 12 (8.3) | 0.002 |
 Glucosidase inhibitor | 80 (54.8) | 66 (45.2) | 60 (41.4) | 0.064 |
 SGLT2 inhibitor | 2 (1.4) | 0 (0.0) | 1 (0.7) | 0.548 |
 OHA | 92 (63.0) | 84 (57.5) | 86 (59.3) | 0.644 |
 Insulin | 4 (2.7) | 8 (5.5) | 26 (17.9) | < 0.001 |